160 related articles for article (PubMed ID: 27069123)
1. Inhibition of Growth by Combined Treatment with Inhibitors of Lactate Dehydrogenase and either Phenformin or Inhibitors of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase 3.
Lea MA; Guzman Y; Desbordes C
Anticancer Res; 2016 Apr; 36(4):1479-88. PubMed ID: 27069123
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Growth of Bladder Cancer Cells by 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one in Combination with Other Compounds Affecting Glucose Metabolism.
Lea MA; Altayyar M; desBordes C
Anticancer Res; 2015 Nov; 35(11):5889-99. PubMed ID: 26504012
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.
Clem B; Telang S; Clem A; Yalcin A; Meier J; Simmons A; Rasku MA; Arumugam S; Dean WL; Eaton J; Lane A; Trent JO; Chesney J
Mol Cancer Ther; 2008 Jan; 7(1):110-20. PubMed ID: 18202014
[TBL] [Abstract][Full Text] [Related]
4. Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma.
Li HM; Yang JG; Liu ZJ; Wang WM; Yu ZL; Ren JG; Chen G; Zhang W; Jia J
J Exp Clin Cancer Res; 2017 Jan; 36(1):7. PubMed ID: 28061878
[TBL] [Abstract][Full Text] [Related]
5. The synergistic effect of PFK15 with metformin exerts anti-myeloma activity via PFKFB3.
Liu X; Zhao Y; Zhang E; Yan H; Lv N; Cai Z
Biochem Biophys Res Commun; 2019 Jul; 515(2):332-338. PubMed ID: 31153642
[TBL] [Abstract][Full Text] [Related]
6. Small molecule 3PO inhibits glycolysis but does not bind to 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3).
Emini Veseli B; Perrotta P; Van Wielendaele P; Lambeir AM; Abdali A; Bellosta S; Monaco G; Bultynck G; Martinet W; De Meyer GRY
FEBS Lett; 2020 Sep; 594(18):3067-3075. PubMed ID: 32620030
[TBL] [Abstract][Full Text] [Related]
7. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.
Clem BF; O'Neal J; Tapolsky G; Clem AL; Imbert-Fernandez Y; Kerr DA; Klarer AC; Redman R; Miller DM; Trent JO; Telang S; Chesney J
Mol Cancer Ther; 2013 Aug; 12(8):1461-70. PubMed ID: 23674815
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation.
Telang S; Clem BF; Klarer AC; Clem AL; Trent JO; Bucala R; Chesney J
J Transl Med; 2012 May; 10():95. PubMed ID: 22591674
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.
O'Neal J; Clem A; Reynolds L; Dougherty S; Imbert-Fernandez Y; Telang S; Chesney J; Clem BF
Breast Cancer Res Treat; 2016 Nov; 160(1):29-40. PubMed ID: 27613609
[TBL] [Abstract][Full Text] [Related]
10. Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.
Li X; Liu J; Qian L; Ke H; Yao C; Tian W; Liu Y; Zhang J
Mol Cell Biochem; 2018 Aug; 445(1-2):123-134. PubMed ID: 29327288
[TBL] [Abstract][Full Text] [Related]
11. Effects of Biguanides on Growth and Glycolysis of Bladder and Colon Cancer Cells.
Lea MA; Kim H; desBORDES C
Anticancer Res; 2018 Sep; 38(9):5003-5011. PubMed ID: 30194144
[TBL] [Abstract][Full Text] [Related]
12. 3PO as a Selective Inhibitor of 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 in A375 Human Melanoma Cells.
Kotowski K; Supplitt S; Wiczew D; Przystupski D; Bartosik W; Saczko J; Rossowska J; Drąg-Zalesińska M; Michel O; Kulbacka J
Anticancer Res; 2020 May; 40(5):2613-2625. PubMed ID: 32366406
[TBL] [Abstract][Full Text] [Related]
13. Combination of 3PO analog PFK15 and siPFKL efficiently suppresses the migration, colony formation ability, and PFK-1 activity of triple-negative breast cancers by reducing the glycolysis.
Kashyap A; Umar SM; Dev J R A; Mathur SR; Gogia A; Batra A; Deo SVS; Prasad CP
J Cell Biochem; 2023 Sep; 124(9):1259-1272. PubMed ID: 37450687
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Warburg Effect in cancer; relationships for 2-arylpyridazinones as inhibitors of the key glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3).
Brooke DG; van Dam EM; Watts CK; Khoury A; Dziadek MA; Brooks H; Graham LJ; Flanagan JU; Denny WA
Bioorg Med Chem; 2014 Feb; 22(3):1029-39. PubMed ID: 24398380
[TBL] [Abstract][Full Text] [Related]
15. 3PO inhibits inflammatory NFκB and stress-activated kinase signaling in primary human endothelial cells independently of its target PFKFB3.
Wik JA; Lundbäck P; la Cour Poulsen L; Haraldsen G; Skålhegg BS; Hol J
PLoS One; 2020; 15(3):e0229395. PubMed ID: 32130250
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anti-cancer effect of phenformin and oxamate.
Miskimins WK; Ahn HJ; Kim JY; Ryu S; Jung YS; Choi JY
PLoS One; 2014; 9(1):e85576. PubMed ID: 24465604
[TBL] [Abstract][Full Text] [Related]
17. PFKFB3 promotes endotoxemia-induced myocardial dysfunction through inflammatory signaling and apoptotic induction.
Tian W; Guo HS; Li CY; Cao W; Wang XY; Mo D; Hao XW; Feng YD; Sun Y; Lei F; Zhang HN; Zhao MG; Li XQ
Toxicol Appl Pharmacol; 2019 Apr; 368():26-36. PubMed ID: 30776389
[TBL] [Abstract][Full Text] [Related]
18. Oxamate targeting aggressive cancers with special emphasis to brain tumors.
Altinoz MA; Ozpinar A
Biomed Pharmacother; 2022 Mar; 147():112686. PubMed ID: 35124385
[TBL] [Abstract][Full Text] [Related]
19. Genetic disruption of lactate/H+ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin.
Marchiq I; Le Floch R; Roux D; Simon MP; Pouyssegur J
Cancer Res; 2015 Jan; 75(1):171-80. PubMed ID: 25403912
[TBL] [Abstract][Full Text] [Related]
20. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer.
Yalcin A; Telang S; Clem B; Chesney J
Exp Mol Pathol; 2009 Jun; 86(3):174-9. PubMed ID: 19454274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
